Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

CAPS Rating: 3 out of 5

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.


Player Avatar weightlossman (< 20) Submitted: 8/30/2010 9:13:01 PM : Outperform Start Price: $6.54 ARNA Score: -134.91

Arena Pharma's (ARNA) Lorcaserin will eventually be approved. It's side effects are benign. Research has shown that it does not cause pulmonary hypertension nor heart-valve damage. Arena has completed much more research than VIVUS did with Qnexa. They are now conducting an additional trials with diabetics. This will confirm health benefits of taking Lorcaserin for those with Type II Diabetes, even if it is just a small amount of weight (5% of body weight). Losing 5% of one's body weight would be exhilarating for 100 million Americans struggling with obesity, as well as those with metabolic syndrome whom have long been discouraged with their inability to lose even a pound for more than a few months. The DM Trial is above and beyond the studies required by the FDA at this point. The trial studies Arena has completed were large > 7,000 participants, compared to the limited Qnexa studies. Regarding Qnexa, Topiramate is one of the two drugs used combined to make Qnexa. Qnexa may be approved, however, the side effects I experienced were severe. I have taken Topamax (Topiramate) and phentermine simultaneously to lose weight. The Topamax has terrible side effects that forced me to stop taking the meds. A large percentage of the participants in Arena's trials lost 20% of their body weight with few side effects other than a mild headache. That's a miracle compared to 1) Xenical's weight loss of 5% along with the nasty dirty underwear side effect 2) The brain numbing side effects from Qnexa or the health risks tied to Meridia. The FDA's scheduling of the Meridia Panel September 15th should have no bearing on the Lorcaserin review. Qnexa and Avandia had nothing to do with each other. They do not set up the reviews of drugs based on the outcome being negative for both candidates. It was a matter of scheduling convenience for the panelists to address both drugs on days running back to back. Other than the profit taking from the recent 100% gains in ARNA, a few downgrades and one or two upgrade in August, combined with general market skids, why is the stock falling as we move closer to Sept 16th? Any feedback is appreciated.

Member Avatar WPThatcher (< 20) Submitted: 9/4/2010 10:36:26 AM
Recs: 1

Weightlossman, I notice that you haven't made any picks. Why would you go through the trouble to right this pitch?

Featured Broker Partners